+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07139990

Personalized Radiotherapy Approaches with Adaptive Planning and Monitoring for Multiple Cancer Types in a Multi-Cohort Platform Trial

Led by University of Texas Southwestern Medical Center · Updated on 2026-08-17

105

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating personalized radiotherapy strategies that adapt standard treatments to individual patient responses across multiple cancer types. This phase 1 multi-cohort platform trial aims to assess the feasibility, safety, and early effectiveness of adaptive radiotherapy approaches combined with systemic therapies in cancers including extensive stage small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck squamous cell carcinoma. The study addresses important questions about timing, dosing, and synergy with immunotherapy to improve patient outcomes. The trial includes four cohorts with distinct treatment approaches. Cohort A uses personalized ultrahypofractionated stereotactic ablative radiotherapy PULSAR for thoracic tumors before chemoimmunotherapy cycles in small cell lung cancer. Cohort B delivers fractionated stereotactic radiosurgery in two pulses for brain metastases, adapting treatment based on interim tumor response. Cohort C combines preoperative PULSAR with immunotherapy for localized soft tissue sarcoma. Cohort D compares neoadjuvant PULSAR or stereotactic ablative radiotherapy with immunotherapy prior to surgery for head and neck cancer. Participants undergo imaging and clinical assessments throughout treatment to monitor tumor response and safety. Outcome measures include safety of PULSAR addition, ability to reduce radiation dose in responsive brain metastases, major wound complication rates in sarcoma, and proportion proceeding to surgery after neoadjuvant therapy. The trial spans several years with ongoing evaluation of disease response, treatment adaptations, and survival outcomes under medical supervision.

CONDITIONS

Brief Title

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

Research Team

S

SARAH NEUFELD

N

NEIL DESAI, MD, MHS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here